Diagnos Inc
XTSX:ADK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Diagnos Inc
Revenue
Diagnos Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Diagnos Inc
XTSX:ADK
|
Revenue
CA$68.2k
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-22%
|
|
|
Biotricity Inc
NASDAQ:BTCY
|
Revenue
$15.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
C
|
CardioComm Solutions Inc
XTSX:EKG
|
Revenue
CA$386.5k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
|
Avricore Health Inc
XTSX:AVCR
|
Revenue
CA$1.9m
|
CAGR 3-Years
32%
|
CAGR 5-Years
101%
|
CAGR 10-Years
32%
|
|
|
N
|
NetraMark Holdings Inc
CNSX:AIAI
|
Revenue
CA$432.5k
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Diagnos Inc
Glance View
Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company is headquartered in Brossard, Quebec. The company went IPO on 2000-09-27. FLAIRE allows for quick modifying and developing of applications, such as CARA (Computer Assisted Retina Analysis). The firm markets CARA, a software platform which assists health specialists in the detection of diabetic retinopathy. CARA is an in-house hosted Web-based application that integrates fundus cameras with an image processing engine over an Internet connection. CARA offers payers and patients in automating the screening process. The CARA suite of applications allows an eye care specialist to clearly visualize both normal retinal landmarks, such as optic nerve, vascular system, macula, fovea, as well as pathological changes (exudates, hemorrhages, micro-aneurisms, neo-vascularization). The firm also offers data mining consulting services in the natural resources sector.
See Also
What is Diagnos Inc's Revenue?
Revenue
68.2k
CAD
Based on the financial report for Dec 31, 2025, Diagnos Inc's Revenue amounts to 68.2k CAD.
What is Diagnos Inc's Revenue growth rate?
Revenue CAGR 10Y
-22%
Over the last year, the Revenue growth was -46%. The average annual Revenue growth rates for Diagnos Inc have been -51% over the past three years , -25% over the past five years , and -22% over the past ten years .
